INTERFERON BETA-1B IS EFFECTIVE IN RELAPSING-REMITTING MULTIPLE-SCLEROSIS .2. MRI ANALYSIS RESULTS OF A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL

被引：1141

作者：

PATY, DW

LI, DKB

DUQUETTE, P

GIRARD, M

DESPAULT, L

DUBOIS, R

KNOBLER, RL

LUBLIN, FD

KELLEY, L

FRANCIS, GS

LAPIERRE, Y

ANTEL, J

FREEDMAN, M

HUM, S

GREENSTEIN, JI

MISHRA, B

MULDOON, J

WHITAKER, JN

EVANS, BK

LAYTON, B

SIBLEY, WA

LAGUNA, J

KRIKAWA, J

PATY, DW

OGER, JJ

KASTRUKOFF, LF

MOORE, GRW

HASHIMOTO, SA

MORRISON, W

NELSON, J

GOODIN, DS

MASSA, SM

GUTTERIDGE, E

ARNASON, BGW

NORONHA, A

REDER, AT

MARTIA, R

EBERS, GC

RICE, GPA

LESAUX, J

JOHNSON, KP

PANITCH, HS

BEVER, CT

CONWAY, K

WALLENBERG, JC

BEDELL, L

VANDENNOORT, S

WEINSHENKER, B

WEISS, W

REINGOLD, S

机构：

[1] UNIV CHICAGO,CHICAGO,IL 60637

[2] HOP NOTRE DAME DE BON SECOURS,MONTREAL H2L 4K8,QUEBEC,CANADA

[3] THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,PHILADELPHIA,PA 19107

[4] MONTREAL NEUROL HOSP & INST,MONTREAL H3A 2B4,QUEBEC,CANADA

[5] UNIV ALABAMA,SCH MED,BIRMINGHAM,AL 35233

[6] UNIV ARIZONA,TUCSON,AZ 85721

[7] MAYO CLIN & MAYO FDN,ROCHESTER,MN 55905

[8] UNIV BRITISH COLUMBIA,VANCOUVER V6T 1W5,BC,CANADA

[9] UNIV CALIF SAN FRANCISCO,SAN FRANCISCO,CA 94143

[10] GEORGETOWN UNIV,WASHINGTON,DC 20057

[11] MCMASTER UNIV,HAMILTON L8S 4L8,ONTARIO,CANADA

[12] NATL MULTIPLE SCLEROSIS SOC,NEW YORK,NY

[13] UNIV WESTERN ONTARIO,UNIV HOSP,LONDON N6A 5A5,ONTARIO,CANADA

[14] BERLEX LABS INC,CEDAR KNOLLS,NJ

[15] UNIV MARYLAND,COLL PK,MD 20742

[16] UNIV CALIF IRVINE,IRVINE,CA 92717

来源：

NEUROLOGY | 1993年 / 43卷 / 04期

关键词：

D O I：

10.1212/WNL.43.4.662

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

We performed yearly MRI analyses on 327 of the total 372 patients in a multicenter, randomized, double-blind, placebo-controlled trial of interferon beta-1b (IFNB). Clinical results are presented in the preceding companion paper. Baseline MRI characteristics were the same in all treatment groups. Fifty-two patients at one center formed a cohort for frequent MRIs (one every 6 weeks) for analysis of disease activity. The MRI results support the clinical results in showing a significant reduction in disease activity as measured by numbers of active scans (median 80% reduction, p = 0.0082) and appearance of new lesions. In addition, there was an equally significant reduction in MRI-detected burden of disease in the treatment as compared with placebo groups (mean group difference of 23%, p = 0.001). These results demonstrate that IFNB has made a significant impact on the natural history of MS in these patients.

引用

页码：662 / 667

页数：6

共 23 条

[1]

[Anonymous], 1990, ANN NEUROL, V27, P591

[2] SERIAL STUDY OF GADOLINIUM-DTPA MRI ENHANCEMENT IN MULTIPLE-SCLEROSIS [J].